Effects of CYP2D6 gene polymorphism 1846G>A on lexotan efficiency and safety in patients with anxiety disorders comorbid with alcoholism
https://doi.org/10.25557/2073-7998.2020.10.60-61
Abstract
Аnxiety disorders are considered a serious problem of psychiatry being comorbid with other states. In this context investigation of factors responsible for unequal drug efficiency and safety in different patients is needed. Among these factors, genetics is considered to be one of the most important. This study assessed the role of CYP2D6 gene polymorphism 1846G>A in Lexotan efficiency and safety in patients with anxiety disorders comorbid with alcoholism.
About the Authors
F. Kh. Zakirov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
M. S. Zastrozhin
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
V. V. Smirnov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
A. E. Petukhov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
E. P. Pankratenko
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. K. Zastrozhina
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Russian Federation
Russian Federation
E. A. Grishina
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Russian Federation
Russian Federation
K. A. Ryzhikova
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Russian Federation
Russian Federation
I. V. Bure
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare
Russian Federation
Russian Federation
V. Yu. Skryabin
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
V. V. Shipitsyn
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. A. Bryun
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
D. A. Sychev
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
T. M. Rozhnova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
References
1. Bandelow B., Michaelis S., Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93-107.
2. Zastrozhin M.S., Skryabin V.Y., Smirnov V.V., Grishina E.A., Ryzhikova K.A., Chumakov E.M., Bryun E.A., Sychev D.A. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Can J Physiol Pharmacol. 2019;97(8):781-785. doi: 10.1139/cjpp-2019-0177.
Review
For citations:
Zakirov F.Kh., Zastrozhin M.S., Smirnov V.V., Petukhov A.E., Pankratenko E.P., Zastrozhina A.K., Grishina E.A., Ryzhikova K.A., Bure I.V., Skryabin V.Yu., Shipitsyn V.V., Bryun E.A., Sychev D.A., Rozhnova T.M. Effects of CYP2D6 gene polymorphism 1846G>A on lexotan efficiency and safety in patients with anxiety disorders comorbid with alcoholism. Medical Genetics. 2020;19(10):60-61. (In Russ.) https://doi.org/10.25557/2073-7998.2020.10.60-61
Views:
483
Email this article 